埃沃胺的一种新型衍生物改善了AD小鼠的认知障碍和突触完整性
Ying-Chun Wan1, Yajun Yang2, Shuo Pang3
1Department of Food Science, National Taiwan Ocean University, Keelung City, Taiwan.
概括
一种新的化合物,LE-42,来自埃沃胺,显示出对阿尔茨海默病 (AD) 治疗的希望. 在AD小鼠模型中,LE-42表明毒性降低和治疗效果增强,改善AD小鼠模型中的记忆和突触完整性.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 生物化学 生物化学
背景情况:
- 阿尔茨海默病 (AD) 是一种进展性神经退行性疾病,影响全球数百万人.
- 目前的AD治疗缺乏足够的预防效果.
- 遗传和环境因素有助于阿尔茨海默病的发病.
研究的目的:
- 评估一种新型的埃沃胺衍生物,LE-42,作为阿尔茨海默病的潜在治疗剂.
- 为了比较LE-42的疗效和安全性,与其母化合物,埃沃胺 (Evo) 相比.
主要方法:
- 在SH-SY5Y和HepaG2细胞中评估LE-42和Evo的细胞毒性.
- 评估了抗氧化和抗细胞毒性对粉样β oligomers (AβOs) 的作用.
- 研究了3×Tg AD小鼠的认知改善,包括记忆和空间学习.
- 分析了病理标志物,如Tau过酸化和突触完整性.
- 研究了JAK2/STAT3通路和关键突触蛋白 (GluN1,GluA2,SYN,PSD95) 的表达.
主要成果:
- LE-42的细胞毒性明显低于Evo.
- LE-42显示出优异的抗氧化和抗AβOs作用.
- 在AD小鼠中,LE-42显著改善了认知功能,并减少了TAU高酸化.
- 通过对特定蛋白质进行上调,LE-42恢复了JAK2/STAT3通路的功能,并增强了突触完整性.
结论:
- LE-42是一种强效的埃沃胺衍生物,对阿尔茨海默氏症有增强的治疗潜力.
- LE-42的有效性可能源于其激活JAK2/STAT3通路的能力,改善突触功能和减少病理.
- LE-42代表了进一步AD药物开发的有希望的候选人.
相关概念视频
01:22Alzheimer's Disease: Treatment
172
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
172
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
114
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
114
01:26Alzheimer's Disease: Overview
456
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
456